🔗 Share this article

As the United States proceeds with historic adjustments to its vaccine recommendations, one figure appears somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has zeroed in on possible fatalities following Covid vaccination in her recent tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to announce sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would put the US out of step with a large portion of the global community with little proof for public health gain. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Dr. Høeg is set to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing specific pediatric vaccine recommendations in the US in order to be more in line with Denmark, a nation with nationalized medicine and a citizenry approximately the population of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no apparent background in drug development, regulation or leadership, which has been typical for previous directors of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a large organization. She is not an expert in industry regulation.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who led the center have had.”

This division has an immense portfolio at the FDA, Woodcock pointed out.

“Many people just pays attention on the innovative therapies, but the generic program approves a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one need to be looked after,” Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the position, which manages over 5,000 employees. “It is a huge leadership role, if you perform it correctly,” she added.

Response and Disputed Programs

In response to questions about Dr. Høeg's fitness for the role and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a spokesperson stated that the “questions stem from inaccurate assumptions”.

“Her resume matches the duties of her job,” the official said, citing the months Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed expedited therapy clearance system that reportedly troubled her preceding directors. “How are these therapies being selected for this voucher program? Who is making the decisions?” Howard questioned. “There is a lot of secrecy going on at the FDA right now.”

Overall, he stated, “the FDA seems to be moving towards more relaxed rules of pharmaceuticals, except for immunizations.”

Established History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if troubling, history, critics observe. She published a analysis using unverified volunteer-provided data to estimate the rate of heart inflammation following Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the current administration included changing guidelines for new vaccines and ending “non-essential” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around true believer who begins with her preconceived notions and reverse-engineers to fit the evidence in a extremely disingenuous, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|